Windtree Therapeutics, Inc. (WINT) Balance Sheet

The consistent decline in asset value, coupled with the shift to negative equity of -$11.6 million in 2025Q3, suggests that the company is rapidly exhausting its financial flexibility. This trajectory implies that the firm is increasingly reliant on external financing to maintain operations, which may further dilute existing shareholders and complicate future capital raising efforts.

The current ratio of 0.33 indicates that current liabilities significantly outweigh current assets, suggesting an acute inability to meet short-term obligations without immediate capital intervention. Investors should monitor this liquidity profile closely, as the current cash runway appears insufficient to support the company's stated research and development objectives.

This transition into negative equity territory suggests that the company's liabilities now exceed its total assets, which may indicate a state of technical insolvency. Such a capital structure often necessitates aggressive restructuring or dilutive equity issuances, which warrants further investigation into the long-term viability of the current corporate strategy.